IL6 and COVID-19: Dysregulation of the immune system in COVID-19 patients has been linked to poor prognosis.[3] Elevated levels of inflammatory markers, including C-reactive protein and interleukins (e.g., IL-1 and IL-6) in the later stages of viral infection indicate the immune origin of worsening respiratory symptoms.[4] Therefore, in addition to antivirals, immunomodulators are considered adjunctive therapies for the management of severe COVID-19 immune overactivation.